According to Citi, Gilead Sciences GILD will continue to reign supreme in HIV.
Citi said that it rates GILD High Risk. “While Gilead has the premier HIV franchise today, future growth depends on the continued ability of Truvada and Atripla to expand the HIV patient pool.”
Gilead Sciences closed on Friday at $41.05.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
